Alzheimer's Life Expectancy Calculator

What is the Global Deterioration Scale (GDS)?

The Global Deterioration Scale, developed by Dr. Barry Reisberg in 1982, divides Alzheimer's disease progression into seven stages. Stages 1 through 3 represent the pre-dementia continuum, from normal cognition through subjective complaints and objective mild impairment. Stage 4 is the earliest stage of true dementia, when a diagnosis is typically confirmed. Stages 5 through 7 cover moderate to severe dementia, culminating in profound cognitive and physical dependence. Clinicians use GDS stage as the single most important factor for estimating remaining life expectancy, because each stage reflects a well-defined set of functional losses that correlate with survival in large cohort studies.

How is Alzheimer's life expectancy estimated?

Published studies consistently identify five main predictors of survival after an Alzheimer's diagnosis: (1) GDS stage at the time of assessment, (2) age at diagnosis, (3) biological sex, (4) overall comorbidity burden, and (5) cognitive function measured by tools such as the Mini-Mental State Examination. Across large cohorts, the median survival from diagnosis is approximately 5.1 years for women and 4.3 years for men (Haaksma et al., Neurology 2020). People diagnosed at age 65 have a median survival of about 8.3 years, while those diagnosed at age 90 survive around 3.4 years on average (Brookmeyer et al., Archives of Neurology 2002). This calculator combines these four main factors - stage, age, sex, and comorbidity - to produce an adjusted range. The underlying model uses exponential survival decay, calibrated to published median and interquartile ranges for each GDS stage.

What factors reduce or extend survival?

Age at diagnosis is the strongest modifier after stage. A diagnosis at 65 roughly doubles expected survival compared to a diagnosis at 85, for the same stage. Comorbidity burden is the next factor this model adjusts for, following Haaksma and colleagues, who included the Charlson Comorbidity Index among the five strongest predictors in their survival tool. The evidence here is not unanimous: the Rountree cohort found that diabetes, hypertension, hyperlipidaemia, coronary disease and cerebrovascular disease measured at baseline did not change survival, so treat the comorbidity adjustment as a rough steer rather than a measured effect. Sex plays a more consistent role: women survive roughly 18% longer on average (5.1 versus 4.3 years in the Swedish registry), a pattern that mirrors the general-population longevity gap. Factors that can modestly extend survival include earlier diagnosis (allowing earlier intervention), participation in structured care programs, physical activity, and social engagement. However, these benefits are modest in late stages, and no treatment currently halts disease progression.

Using these estimates for care planning

Survival estimates are planning tools, not prophecies. Individual courses vary enormously: the published range for Stage 4, for example, spans 3 to 8 years. Use the median estimate to start conversations about advance care directives, legal and financial planning, caregiver support, and hospice eligibility. At Stage 5 and above, the person with Alzheimer's typically requires full-time assistance with daily activities, and families benefit from understanding what professional home care or memory-care facilities involve. At Stage 7, palliative and hospice care focuses on comfort rather than curative treatment, and most families benefit from early engagement with a palliative care team. These numbers are best interpreted with a geriatrician, neurologist, or palliative medicine specialist who knows the full clinical picture.